ClinicalTrials.gg
CompletedNCT06429306Updated Aug 26, 2024

Study of Dexycu in Treating Intraocular Inflammation

A Phase 3 interventional study of Dexycu and Placebo in Inflammation and Cataract, sponsored by Ocumension Therapeutics (Shanghai) Co., Ltd. Completed at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.

Primary conditionCataractRegistry: InflammationReclassifiedWhy we changed it
Registry
Inflammation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cataract
Why
  1. Inflammation is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Cataract.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 2 years 11 months ago, and no results have been posted to the registry.
  • Registered 1 year 8 months after the study started (first participant enrolled Aug 2022, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.

Enrollment
5th of 34
285 · median 50
Started
2022
with 5 others
Phase 3
9 of 34
1 open now
Registered
30th of 34
by date
Lead sponsor
2 of 34
Ocumension Therapeutics (Shanghai) Co., Ltd

Among the 34 studies testing dexamethasone in Cataract, this one is the 5th largest by enrollment, is one of 6 that started in 2022, is one of 9 in phase 3, and was the 30th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing dexamethasone in Cataract, or all of them as a file.
02

Study summary

This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of inflammation associated with cataract surgery.

Read the detailed description

This is a prospective, randomized, double-blindmasked, placebo-controlled, parallel- design, multicenter study of subjects over 40 years undergoing cataract surgery. Subjects meet the inclusion criteria and do not meet any exclusion criteria are randomiszed to the dexamethasone implant group or placebo group at a ratio of 2:1.

Subjects received a single does injection in the study eye immediately after the completion of cataract surgery. The investigational drug comes with a special injection device and injection guide.

All subjects will be administered to the study eye with quinolone topical antibiotic eye drops or their equivalent 3 days before and 7 days after surgery.

03

Conditions studied

  • Inflammation
  • Cataract

Browse trials for

Keywords

  • Cataract Surgery
  • Postoperative Inflammation
04

In context

Cataract Reclassified

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

This study's enrollment of 285 is above the median of 79 across 1,094 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Ocumension Therapeutics (Shanghai) Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.

Compared within Cataract, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient must provide written by signing the Informed Consent approved by the Institutional Review Board (IRB).
  2. Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation.
  3. The patient must demonstrate best corrected visual acuity (BCVA) of 20/30-20/200 in the study eye and better than 20/200 in the fellow eye.
  4. The patient must be considered by the Investigator to have visual acuity potential. greater than 20/30 in the study eye.
  5. The patient must have a corneal endothelial cell count by specular microscopy in the study eye of at least 2000 cells/mm2 with normal cell morphology.
  6. A female patient of must have a negative pregnancy test on Day 0 and be using an effective method of from Screening for the duration of the study.
  7. The patient must be willing and able to understand and comply with the study procedures and to communicate meaningfully with study personnel.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have used any ocular, topical or oral within 7 days prior to Day 0.
  2. Patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening.
  3. Patients who have received any intravitreal corticosteroid delivery vehicle (e.g.,Retisert, Ozurdex, Iluvien) in the study eye at any time.
  4. Patients who anticipate requiring treatment with any corticosteroids( by any route,except inhalation), during the study.
  5. Patients with an allergy or to dexamethasone.
  6. Patients who are known steroid responders (corticosteroid-related intraocular pressure elevation in either eye).
  7. Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to Day 0.
  8. Patients who have undergone prior intraocular (non-laser) surgery in the study eye within 6 months prior to screening.
  9. Patients who have undergone prior intraocular laser surgery in the study eye within 3 months prior to screening.
  10. Patients with planned intraocular or laser surgery in the study eye for the duration of the study.
  11. Patients with any signs of intraocular inflammation in either eye at screening.
  12. Patients with evidence of corneal abnormality or dystrophy (e.g. opacities, guttae,clouding, etc.) or an inability to obtain an acceptable specular micrograph at Screening.
  13. Patients with a history of chronic uveitis from any cause in either eye.
  14. Patients who have received any prior intravitreal injections in the study eye.
  15. Patients with glaucomatous optic neuropathy or glaucomatous visual field loss in either eye.
  16. Patients with ocular hypertension with an IOP in the study eye > 21 mm Hg at Screening with or without treatment with anti-glaucoma monotherapy.
  17. Patients with ocular hypertension receiving treatment with two or more anti-glaucoma Medications.
  18. Patients treated with any product within 30 days prior to screening or patients enrolled previouslyc study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Dexamethasone intraocular injection

    Dexamethasone implant single injection in the treatment eye after cataract surgery.

    Drug: Dexycu

  • Placebo comparator
    Placebo

    Blank placebo single injection in the treatment eye after cataract surgery.

    Drug: Placebo

Interventions

  • DrugDexycu

    5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone

    Also known as: Investigational product

  • DrugPlacebo

    Acetyl triethyl citrate

07

What researchers measure

Primary outcomes

  1. Anterior chamber cell clearing rate

    The primary efficacy outcome is anterior chamber cell clearing in the study eye at Day 8. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).

    Time frame: DAY 8

Secondary outcomes

  1. Anterior chamber cell clearing rates

    The secondary efficacy outcome is anterior chamber cell clearing in the study eye at Day 1 \& 3 \& 15 \& 30. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).

    Time frame: DAY 1 & 3 & 15 & 30

  2. Anterior chamber flare clearing rates

    Percentage of subjects with anterior chamber flare grade 0 at Day 1, 3, 8, 15, and 30. The slit lamp examination for anterior chamber flare (ACF) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent), grade 1 (trace), grade 2 (mild intensity), grade 3 (moderate intensity), or grade 4 (strong intensity). Anterior chamber flare clearing occurs when all the ACC are absent (grade 0).

    Time frame: DAY 1 & 3 & 8 & 15 & 30

  3. Anterior chamber cell & flare clearing rates

    The secondary efficacy outcome is anterior chamber cell \& flare clearing in the study eye at Day 1 \& 3 \& 15 \& 30. The slit lamp examination for anterior chamber cells \& flare (ACCF) is a recognized way to measure inflammation in the anterior chamber.

    Time frame: DAY 1 & 3 & 15 & 30

  4. Mean anterior chamber cell score and mean anterior chamber flare score

    Calculate the mean score of anterior chamber cell and flare separately at Day 8 and 15.

    Time frame: DAY 8 & 15

  5. Mean anterior chamber cell + flare score

    Calculate the mean socre of anterior chamber cell + flare at Day 8 and 15.

    Time frame: DAY 8 &15

08

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Nov 2023, 15 months.

Of 23 industry-sponsored phase 3 interventional studies under Cataract, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 31 studies reached it within 13 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2024
First posted
May 24, 2024
StartActual
Aug 22, 2022
Primary completionActual
Nov 24, 2023
CompletionActual
Apr 9, 2024
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06429306
Lead sponsor
Ocumension Therapeutics (Shanghai) Co., Ltd
Responsible party
Sponsor
First posted
May 24, 2024
Start date
Aug 22, 2022
Primary completion
Nov 24, 2023
Completion
Apr 9, 2024
Last update
Aug 26, 2024

Study contacts

Zhixun Li
study director · Ocumension Therapeutics (Shanghai) Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion